In a report released on October 8, Luca Issi from RBC Capital maintained a Buy rating on Argenx Se. The company’s shares closed yesterday at $804.90.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Issi is a 4-star analyst with an average return of 5.4% and a 39.94% success rate. Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ionis Pharmaceuticals, and uniQure.
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $842.25, implying a 4.64% upside from current levels. In a report released on October 2, Goldman Sachs also maintained a Buy rating on the stock with a $916.00 price target.
The company has a one-year high of $807.91 and a one-year low of $510.06. Currently, Argenx Se has an average volume of 388.7K.
Read More on ARGX:
Disclaimer & DisclosureReport an Issue
- Argenx SE Calls Extraordinary Shareholder Meeting for November 2025
- Argenx price target raised to $1,040 from $766 at Morgan Stanley
- Vor Bio appoints Khan as Chief Medical Affairs Officer
- Argenx price target raised to $882 from $797 at Stifel
- Argenx Completes Phase 1 Study on ARGX-109: Key Insights for Investors
/Semiconductor%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
